General Oncology, Inc.
Clinical-stage biopharmaceutical company developing first-in-class therapies for metastatic and proliferative diseases. Focus areas include repurposed combination chemotherapy regimens that impair tumor DNA repair, discovery of ultra-high potency small molecules that cross-link DNA, and clinical development of these candidates through IND-enabling studies and early-phase trials. The company sponsors investigator-collaborative trials and presents clinical data at scientific conferences.
Industries
N/A
Products
Repurposed combination regimen for BRCA-mutated cancers (clinical-stage)
A clinical-stage repurposed multi-drug regimen combining DNA cross-linking and redox-modulating agents with autologous stem cell rescue to impair tumor DNA repair and sensitize cancer cells to cytotoxic therapy for BRCA/PALB2-mutated pancreatic and breast cancers.
Preclinical ultra-high potency DNA cross-linking small-molecule candidates
Discovery-stage portfolio of novel small molecules believed to irreversibly cross-link DNA, being advanced toward IND-enabling studies for indications including solid tumors and hematologic malignancies.
Repurposed combination regimen for BRCA-mutated cancers (clinical-stage)
A clinical-stage repurposed multi-drug regimen combining DNA cross-linking and redox-modulating agents with autologous stem cell rescue to impair tumor DNA repair and sensitize cancer cells to cytotoxic therapy for BRCA/PALB2-mutated pancreatic and breast cancers.
Preclinical ultra-high potency DNA cross-linking small-molecule candidates
Discovery-stage portfolio of novel small molecules believed to irreversibly cross-link DNA, being advanced toward IND-enabling studies for indications including solid tumors and hematologic malignancies.
Services
Sponsor and operator of early-phase oncology clinical trials
Sponsorship and operational oversight of investigator-collaborative Phase 1 trials evaluating combination regimens in BRCA/PALB2-mutated cancers, with planned expansion to broader populations.
Sponsor and operator of early-phase oncology clinical trials
Sponsorship and operational oversight of investigator-collaborative Phase 1 trials evaluating combination regimens in BRCA/PALB2-mutated cancers, with planned expansion to broader populations.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Oncology drug development
- Combination chemotherapy repurposing
- DNA cross-linking small-molecule discovery
Key Technologies
- DNA cross-linking agents
- Redox modulation to impair DNA repair
- Autologous stem cell infusion
- Repurposed combination chemotherapy regimens